Traders Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)

Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Monday. $61.80 million flowed into the stock on the tick-up and $145.95 million flowed out of the stock on the tick-down, for a money net flow of $84.15 million out of the stock. Of all companies tracked, Johnson & Johnson had the 0th highest net out-flow for the day. Johnson & Johnson traded up $0.23 for the day and closed at $133.45

JNJ has been the subject of several recent research reports. BidaskClub raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $128.00 target price on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price for the company. in a report on Friday, July 21st. Jefferies Group LLC reaffirmed a “hold” rating and set a $145.00 target price (up from $140.00) on shares of Johnson & Johnson in a report on Friday, July 14th. Finally, Citigroup Inc. assumed coverage on shares of Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 target price for the company. Five equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $135.45.

The company has a market cap of $359.39 billion, a PE ratio of 22.66 and a beta of 0.78. The stock’s 50 day moving average price is $132.27 and its 200-day moving average price is $130.03.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter last year, the business posted $1.74 earnings per share. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Lynch & Associates IN boosted its stake in shares of Johnson & Johnson by 0.9% during the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after acquiring an additional 841 shares during the last quarter. Oakbrook Investments LLC boosted its stake in shares of Johnson & Johnson by 7.4% during the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after acquiring an additional 9,375 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Johnson & Johnson during the first quarter valued at $1,731,000. Bollard Group LLC boosted its stake in shares of Johnson & Johnson by 5.0% during the second quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock valued at $1,263,000 after acquiring an additional 459 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. boosted its stake in shares of Johnson & Johnson by 278.0% during the second quarter. Adams Diversified Equity Fund Inc. now owns 241,900 shares of the company’s stock valued at $32,001,000 aft

JNJ has been the subject of several recent research reports. BidaskClub raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $128.00 target price on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price for the company. in a report on Friday, July 21st. Jefferies Group LLC reaffirmed a “hold” rating and set a $145.00 target price (up from $140.00) on shares of Johnson & Johnson in a report on Friday, July 14th. Finally, Citigroup Inc. assumed coverage on shares of Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 target price for the company. Five equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $135.45.

The company has a market cap of $359.39 billion, a PE ratio of 22.66 and a beta of 0.78. The stock’s 50 day moving average price is $132.27 and its 200-day moving average price is $130.03.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter last year, the business posted $1.74 earnings per share. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Lynch & Associates IN boosted its stake in shares of Johnson & Johnson by 0.9% during the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after acquiring an additional 841 shares during the last quarter. Oakbrook Investments LLC boosted its stake in shares of Johnson & Johnson by 7.4% during the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after acquiring an additional 9,375 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Johnson & Johnson during the first quarter valued at $1,731,000. Bollard Group LLC boosted its stake in shares of Johnson & Johnson by 5.0% during the second quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock valued at $1,263,000 after acquiring an additional 459 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. boosted its stake in shares of Johnson & Johnson by 278.0% during the second quarter. Adams Diversified Equity Fund Inc. now owns 241,900 shares of the company’s stock valued at $32,001,000 after acquiring an additional 177,900 shares during the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Traders Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://ledgergazette.com/2017/10/11/traders-sell-shares-of-johnson-johnson-jnj-on-strength-jnj-3.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply